Cytophage Announces Resignation of Director

Winnipeg – May 1, 2026 – TheNewswire — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO; FSE: 70G) announces that, as disclosed in the Company’s management’s discussion and analysis for the year ended December 31, 2025 filed on April 30, 2026, Mr. Will Ollerhead has resigned as a director of the Company effective April 29, 2026, to focus on other endeavors. The Company thanks him for his service and contributions during his tenure as a director and wishes him continued success in the future.

About Cytophage 

Cytophage (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. 

For more information on Cytophage, please visit www.cytophage.com.

For further information please contact:  

Cytophage Technologies Ltd.

Steven Theriault, Chief Executive Officer: [email protected]

Investor Relations: [email protected]

Cytophage Investor Alerts: https://cytophage.com/subscribe/

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release. 

Copyright (c) 2026 TheNewswire – All rights reserved.